Biohaven Shares Rise After FDA Accepts Vyglxia Resubmission for Review

03:30 PM EDT, 10/22/2026 (MT Newswires) -- Biohaven (BHVN) shares were up roughly 26% in Thursday trading after the company said the US Food and Drug Administration has accepted its resubmitted new drug application for Vyglxia (troriluzole) for review in spinocerebellar ataxia. The FDA considers the resubmission a complete response to its Nov. 4, 2025 action letter and set a target decision date in Q1 2027, the company said. The agency plans an advisory committee meeting to gather outside input and will announce the date later, it added. Price: 14.80, Change: +3.05, Percent Change: +25.91